The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Background The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Jg. 124; H. 21; S. 4241 - 4247
Hauptverfasser:	DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.11.2018 John Wiley and Sons Inc
Schlagworte:	Children Complications Enzyme inhibitors Evaluation Fibrosarcoma infantile fibrosarcoma Inhibitors larotrectinib local control Morbidity neurotrophic receptor tyrosine kinase (NTRK) Oncology Original Patients pediatric Pediatrics Sarcoma Solid tumors Surgery Therapy Tropomyosin tropomyosin receptor kinase (TRK) fusion Tumors Wound healing larotrectinib sarcoma tropomyosin receptor kinase (TRK) fusion local control neurotrophic receptor tyrosine kinase (NTRK) infantile fibrosarcoma pediatric surgery
ISSN:	0008-543X, 1097-0142, 1097-0142
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!